Abilify
The Litigation Group will educate members about Abilify and keep them apprised of the status of litigation through litigation group meetings, the group’s list server, and the sharing of materials.
Join Litigation GroupAbilify
Abilify is a widely prescribed, atypical, anti-psychotic prescription medicine developed and marketed by Bristol-Myers Squibb Company, Otsuka Pharmaceutical Co., Ltd, and various Otsuka subsidiaries. In many patients, Abilify causes uncontrollable behaviors such as compulsive gambling. The manufacturers warn about this side effect in Europe and Canada but not in the United States. Internal company documents acknowledge a plausible biological mechanism based on the long-known relationship of dopamine (upon which Abilify acts in the brain) and compulsive gambling.
The Litigation Group will educate members about Abilify and keep them apprised of the status of litigation through Litigation Group meetings, the group’s list server, and the sharing of materials.
Dues
$300 annually
Litigation Group members, visit AAJ's Community Center to connect with your colleagues, search discussion archives, download documents, update your list server settings, and more. Lit Group Member Login
